PARK2-STRADA Fusion FISH Probe
The PARK2-STRADA Fusion FISH Probe is used to confirm a fusion of the PARK2 and STRADA genes. The fusion of the PARK2 and STRADA genes has been associated with Brain Lower Grade Glioma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| PARK2-STRADA-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-RERE | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-REOR | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-REGO | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-REGR | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-OROR | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-GORE | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-GROR | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| PARK2-STRADA-20-AQAQ | 20 (40 μL) | 200 μL |
|
STRADA Gene Summary
The protein encoded by this gene contains a STE20-like kinase domain, but lacks several residues that are critical for catalytic activity, so it is termed a 'pseudokinase'. The protein forms a heterotrimeric complex with serine/threonine kinase 11 (STK11, also known as LKB1) and the scaffolding protein calcium binding protein 39 (CAB39, also known as MO25). The protein activates STK11 leading to the phosphorylation of both proteins and excluding STK11 from the nucleus. The protein is necessary for STK11-induced G1 cell cycle arrest. A mutation in this gene has been shown to result in polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) syndrome. Multiple transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their full-length nature is not known. [provided by RefSeq, Sep 2009]
Gene Name: STE20-related Kinase Adaptor Alpha
Chromosome: CHR17: 61780191 -61819330
Locus: 17q23.3
Gene Diseases
The PARK2 STRADA Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Brain Lower Grade Glioma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|